Back to search

Peptide record

TPDB08541

Antibacterial Anticancer Toxicity standard
17 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB08541
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia
standard
No
A 17-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
HKCAKIKWRGVHVKYCA
Physicochemical Analysis
C92H147N29O19S2
NDEQLMFPST
K
2027.48
10.31
7
0
7
+5
2.92
-0.447
68.82
Mammalian: 3.5 hour Yeast: 10 min E.coli: >10 hour
7115
350.93
3
Residue Composition
number
2
A
1
R
0
N
0
D
2
C
0
E
0
Q
1
G
2
H
1
I
0
L
4
K
0
M
0
F
0
P
0
S
0
T
1
W
1
Y
2
V
Amino Acid Distribution
A: 2 R: 1 N: 0 D: 0 C: 2 E: 0 Q: 0 G: 1 H: 2 I: 1 L: 0 K: 4 M: 0 F: 0 P: 0 S: 0 T: 0 W: 1 Y: 1 V: 2
Chemical Descriptors
17
C92H147N29O19S2
2027.48
10.31
+5
2.92
-0.447
Evidence Records 7 records
Evidence 1 Activity

Activity

9% Hemolysis
Toxicity
500 µg/mL
Hemolytic Cytotoxic
9% Hemolysis | 500 | µg/mL | target cell: Sheep erythrocytes

Target

Sheep erythrocytes

Source & Reference

NA
DBAASP
In vitro activity of novel in silico-developed antimicrobial peptides against a panel of bacterial pathogens. | J Pept Sci | 2013
Evidence 2 Activity

Activity

6% Hemolysis
Toxicity
250 µg/mL
Hemolytic Cytotoxic
6% Hemolysis | 250 | µg/mL | target cell: Sheep erythrocytes

Target

Sheep erythrocytes

Source & Reference

NA
DBAASP
In vitro activity of novel in silico-developed antimicrobial peptides against a panel of bacterial pathogens. | J Pept Sci | 2013
Evidence 3 Activity

Activity

6% Hemolysis
Toxicity
100 µg/mL
Hemolytic Cytotoxic
6% Hemolysis | 100 | µg/mL | target cell: Sheep erythrocytes

Target

Sheep erythrocytes

Source & Reference

NA
DBAASP
In vitro activity of novel in silico-developed antimicrobial peptides against a panel of bacterial pathogens. | J Pept Sci | 2013
Evidence 4 Activity

Activity

1% Hemolysis
Toxicity
12.5 µg/mL
Hemolytic Cytotoxic
1% Hemolysis | 12.5 | µg/mL | target cell: Sheep erythrocytes

Target

Sheep erythrocytes

Source & Reference

NA
DBAASP
In vitro activity of novel in silico-developed antimicrobial peptides against a panel of bacterial pathogens. | J Pept Sci | 2013
Evidence 5 Activity

Activity

6% Cytotoxicity
Toxicity
100 µg/mL
Cytotoxic
6% Cytotoxicity | 100 | µg/mL | target cell: Human umbilical vein endothelial cells HUVEC

Target

Human umbilical vein endothelial cells HUVEC

Source & Reference

NA
DBAASP
In vitro activity of novel in silico-developed antimicrobial peptides against a panel of bacterial pathogens. | J Pept Sci | 2013
Evidence 6 Activity

Activity

3% Cytotoxicity
Toxicity
100 µg/mL
Cytotoxic
3% Cytotoxicity | 100 | µg/mL | target cell: Human fibroblasts WI-38

Target

Human fibroblasts WI-38

Source & Reference

NA
DBAASP
In vitro activity of novel in silico-developed antimicrobial peptides against a panel of bacterial pathogens. | J Pept Sci | 2013
Evidence 7 Activity

Activity

% Hemolysis
Toxicity
1 %
Hemolytic Cytotoxic
Hemolytic_activity: [Ref.23893489] <1% hemolysis at 1 µg/ml , <1% hemolysis at 12.5 µg/ml , 5.73% hemolysis at 100 µg/ml , 6.4% hemolysis at 250 µg/ml , 9.4% hemolysis at 500 µg/ml against sheep red blood cells | Cytotoxicity: [Ref.23893489] The cytotoxicity (vs control) of P2041 is 6% against HUVEC (endothelial) cells at a peptide concentration of 100 µg/ml. ##The cytotoxicity (vs control) of P2041 is 3% agaisnt WI-38 (fibroblast) cells at a peptide concentration of 100 µg/m

Target

erythrocytes

Source & Reference

NA
DRAMP
J Pept Sci. 2013 Sep 19(9):554-65. doi: 10.1002/psc.2532.